478 reports of this reaction
1.7% of all DOLUTEGRAVIR SODIUM reports
#12 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #12 most commonly reported adverse reaction for DOLUTEGRAVIR SODIUM, manufactured by ViiV Healthcare Company. There are 478 FDA adverse event reports linking DOLUTEGRAVIR SODIUM to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 1.7% of all 28,565 adverse event reports for this drug.
Patients taking DOLUTEGRAVIR SODIUM who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for DOLUTEGRAVIR SODIUM, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for DOLUTEGRAVIR SODIUM:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 478 FDA reports for DOLUTEGRAVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 1.7% of all adverse event reports for DOLUTEGRAVIR SODIUM, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking DOLUTEGRAVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.